Clinical trials: Post-menopausal Women
Breast Cancer
S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using drugs such as anastrozole and fulvestrant may fight breast cancer by blocking the use of estrogen.
- Trial name
- NCT00075764
- Testing
- anastrozole, fulvestrant
- Where
- 426 sites in United States, Canada
- Volunteers
- 695 people
- Sponsor
- SWOG Cancer Research Network
Breast Cancer
A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause
The purpose of this study is to learn about the effects of the study medicine PF-07220060 plus letrozole, compared with the effects of taking letrozole alone without PF-07220060 for treatment of breast cancer.
- Trial name
- NCT06465368
- Testing
- PF-07220060, letrozole
- Where
- 51 sites in United States, Australia and 11 more
- Volunteers
- 121 people
- Sponsor
- Pfizer
Menopause, Depression
Brain Imaging Study in Menopausal Women With and Without Major Depressive Disorder
The purpose this study is to measure cortical gama-aminobutyric acid levels (GABA) levels in menopausal women with major depressive disorder and healthy subjects using nuclear magnetic resonance spectroscopy (MRS).
- Trial name
- NCT00626340
- Testing
- MDD diagnosis and Estrogen treatment, MDD diagnosis and Fluoxetine treatment, MDD diagnosis with both Estrogen and Fluoxetine treatment
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Breast Cancer, Cancer of the Breast
Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer
This purpose of this trial is to show that the combination of Avastin and hormone therapy should be more effective than hormone therapy alone for the treatment of breast cancer.
- Conditions
- Breast Cancer, Cancer of the Breast, Breast Neoplasm
- Trial name
- NCT00530868
- Testing
- Letrozole (Femara), Letrozole; Avastin
- Where
- 7 sites in United States
- Volunteers
- 75 people
- Sponsor
- University of Alabama at Birmingham
Advanced Breast Cancer
Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant
The study was designed to identify and register practical observations and experiences in connection with planning and implementing decentralized, patient-centered clinical trials at a geographic distance with virtual elements.
- Trial name
- TELEPIK (NCT04862143)
- Testing
- Alpelisib, Fulvestrant, Goserelin
- Where
- Sweden
- Volunteers
- 2 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
STRIDE - STimulating Immune Response In aDvanced brEast Cancer
EMD Serono has decided to permanently terminate the trial EMR 200038-010 (STRIDE) in the indication of breast cancer following the clinical hold on the investigational new drug application for tecemotide (L-BLP25).
- Trial name
- STRIDE (NCT00925548)
- Testing
- Tecemotide (L-BLP25) and Hormonal Treatment, cyclophosphamide, sodium chloride (NaCl)
- Where
- 29 sites in United States, Australia and 10 more
- Volunteers
- 16 people
- Sponsor
- EMD Serono
Pharmacokinetics
Open-Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Tamoxifen When Coadministered To Healthy Post-Menopausal Female Subjects
The goal of this study is to evaluate the effect of multiple doses of Desvenlafaxine SR on the pharmacokinetics of Tamoxifen and endoxifen when coadministered to healthy post-menopausal female subjects.
- Trial name
- NCT01189500
- Testing
- Tamoxifen, Tamoxifen and Desvenlafaxine Succinate Sustained Release
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Pfizer
Gynecology
An Endometrial Cancer Chemoprevention Study of Metformin
The goal of this clinical research study is to learn about the effects of metformin and/or a program called "lifestyle intervention" on the endometrium (inner lining of the uterus) in post-menopausal women who are also obese…
- Trial name
- NCT01697566
- Testing
- Metformin, Endometrial Biopsy, Lifestyle Intervention
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Obesity
Celecoxib Inhibition of Aromatase Expression and Inflammation in Adipose Tissue of Obese Postmenopausal Women
The study plans to find out whether Celebrex may be potentially useful to decrease inflammation in fat tissues and thereby lower the production of substances such as estrogens that may increase the risk of developing breast…
- Trial name
- NCT01901679
- Testing
- Celebrex
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
Post Menopausal Osteoporosis
Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis
This study will compare the effectiveness of denosumab treatment every 6 months with once yearly zoledronic acid treatment on bone mineral density (BMD) at various skeletal sites.
- Trial name
- NCT01732770
- Testing
- Denosumab, Zoledronic Acid
- Where
- 45 sites in United States, Australia and 5 more
- Volunteers
- 643 people
- Sponsor
- Amgen
Osteoporosis
A Phase II Study Evaluating SB-751689 in Post-Menopausal Women With Osteoporosis.
This is a 12 month study designed to evaluate the safety and effectiveness of SB-751689 in the treatment of osteoporosis in post-menopausal women, in comparison with 2 active comparators and placebo.
- Trial name
- NCT00471237
- Testing
- Ronacaleret, Teriparatide, Alendronate
- Where
- 49 sites in United States, Argentina and 12 more
- Volunteers
- 564 people
- Sponsor
- GlaxoSmithKline
Breast Cancer
A Study of LY3484356 in Women With Breast Cancer Before Having Surgery
The purpose for this study is to see if the study drug, LY3484356, is safe and to determine what effects it has on breast cancer in participants with Estrogen Receptor Positive (ER+), HER2 Negative (HER2-) early stage (stage…
- Trial name
- EMBER-2 (NCT04647487)
- Testing
- LY3484356
- Where
- 19 sites in United States, Belgium and 4 more
- Volunteers
- 87 people
- Sponsor
- Eli Lilly and Company
Vulvovaginal Atrophy, Dyspareunia
Vulvoscopy Changes of the Vulva, Vestibule and Vagina With Daily Ospemifene in Women With Dyspareunia From VVA
This is an unblinded study to be conducted at a single research center, San Diego Sexual Medicine. Subjects meeting inclusion and exclusion criteria will receive 60 mg ospemifene daily for twenty weeks.
- Trial name
- NCT02784613
- Testing
- Ospemifene
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Sue Goldstein
Breast Cancer
Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer.
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by blocking the use of estrogen by the tumor cells.
- Trial name
- NCT00611715
- Testing
- erlotinib hydrochloride, letrozole, fluorescence in situ hybridization
- Where
- 9 sites in United States
- Volunteers
- 48 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Breast Cancer, DCIS
CyberKnife Stereotactic Accelerated Partial Breast Irradiation (SAPBI)
This study will prospectively evaluate the technical feasibility, acute toxicity, late effects and oncologic outcomes of CyberKnife Stereotactic Accelerated Partial Breast Irradiation (CK-SAPBI) in early stage breast cancer.
- Conditions
- Breast Cancer, DCIS, Invasive Ductal Carcinoma
- Trial name
- CK-SAPBI (NCT02365714)
- Testing
- CK Stereotactic Accelerated Partial Breast Irradiation
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Georgetown University
Post Menopausal Osteoporosis
DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
This study will assess the efficacy and safety of intravenous administration of Bonviva regimens in women with post-menopausal osteoporosis, compared to oral daily administration.
- Trial name
- NCT00048074
- Testing
- ibandronate [Bonviva/Boniva]
- Where
- 64 sites in United States, Australia and 14 more
- Volunteers
- 1,395 people
- Sponsor
- Hoffmann-La Roche
Osteoporosis
Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density
This study will compare the effects of Zoledronic acid and Raloxifene in reducing bone turnover markers in postmenopausal women with low bone mineral density over 6 months.
- Trial name
- NCT00431444
- Testing
- Raloxifene, Zoledronic acid
- Where
- 17 sites in United States
- Volunteers
- 110 people
- Sponsor
- Novartis
Postmenopausal Symptoms, Aging
Cholinergic Health After Menopause (CHAMP)
Women are at increased risk for Alzheimer's disease (AD). Notably at menopause, some women experience a change in cognition. However, not all women experience negative effects of menopause on cognition.
- Conditions
- Postmenopausal Symptoms, Aging, Alzheimer Disease
- Trial name
- CHAMP (NCT04129060)
- Testing
- Cholinergic antagonist
- Where
- 2 sites in United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- University of Vermont
Breast Carcinoma, Breast Ductal Carcinoma In Situ
EMBr Wave for the Reduction of Hot Flashes in Women With a History of Breast Cancer
This trial studies how well EMBr Wave technology works in reducing hot flashes in women with a history of breast cancer. Hot flashes are a common symptom experienced by menopausal women.
- Conditions
- Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ, Hot Flashes
- Trial name
- NCT05086705
- Testing
- EMBr Wave, Questionnaire Administration
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Osteopenia
Heartland Osteoporosis Prevention Study
The purpose of this study is to identify the best way to prevent bone loss in the first years after menopause. The HOPS study will compare bone loss at 12 months in women: 1) who take calcium and vitamin D only; 2) who take…
- Trial name
- HOPS (NCT02186600)
- Testing
- Calcium Carbonate, Vitamin D3, Risedronate
- Where
- United States
- Volunteers
- 276 people
- Sponsor
- University of Nebraska